⌘K
Loading ticker…
Tarsus Pharmaceuticals, Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, Tarsus Pharmaceuticals, Inc. Common Stock (TARS) has a 3-month relative strength percentile of 30 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 51. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 4.8%, relative volume 3.04×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
30 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
TARS is in a stage 1 base, week 2. Currently in a 125-day base; basing ADR 4.7% (broad 4.3%). VCP detected: inconclusive. RS line below base-start high. Distance from 50d / 200d: 0.7% / -8.1%.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
TARS is held by 6 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $90M notional. Top 3 carry $188M.
Top 6 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $90M |
| IWMiShares Russell 2000 ETF | 0.09% | $68M |
| VXFVanguard Extended Market ETF | 0.04% | $31M |
| IWOiShares Russell 2000 Growth ETF | 0.19% | $23M |
| XPHState Street SPDR S&P Pharmaceuticals ETF | 1.92% | $6M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $4M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | TARS Jan avg: 4.48% median: 2.30% win: 50% σ: 23.27% n: 4 2022-04-12 → 2026-05-29 | TARS Feb avg: 9.59% median: 7.65% win: 50% σ: 24.82% n: 4 2022-04-12 → 2026-05-29 | TARS Mar avg: -3.84% median: -6.00% win: 25% σ: 14.27% n: 4 2022-04-12 → 2026-05-29 | TARS Apr avg: -0.37% median: 1.05% win: 60% σ: 12.47% n: 5 2022-04-12 → 2026-05-29 | TARS May avg: -6.33% median: -6.62% win: 40% σ: 15.29% n: 5 2022-04-12 → 2026-05-29 | TARS Jun avg: -2.29% median: 0.25% win: 50% σ: 11.82% n: 4 2022-04-12 → 2026-05-29 (current) | TARS Jul avg: 2.47% median: -0.65% win: 50% σ: 14.02% n: 4 2022-04-12 → 2026-05-29 | TARS Aug avg: 11.12% median: 7.00% win: 75% σ: 29.75% n: 4 2022-04-12 → 2026-05-29 | TARS Sep avg: 8.89% median: 6.40% win: 100% σ: 9.50% n: 4 2022-04-12 → 2026-05-29 | TARS Oct avg: 9.70% median: 11.69% win: 75% σ: 22.87% n: 4 2022-04-12 → 2026-05-29 | TARS Nov avg: 10.36% median: 16.14% win: 75% σ: 12.76% n: 4 2022-04-12 → 2026-05-29 | TARS Dec avg: 4.42% median: 3.98% win: 75% σ: 14.48% n: 4 2022-04-12 → 2026-05-29 |